Development of a novel antibody biomanufacturing system and first application to the human target first-in-class TYRO3 in oncology

Identity card

Global budget: 3 197 k€

Public funding: 1 571 k€

Public funders: Fonds Unique Interministériel (FUI) – DGCIS/Oséo, Grand Lyon, Région Rhône-Alpes (FEDER Alsace, Eurométropole de Strasbourg )

Call for projects: FUI

Year start: 2015

Ongoing project

Accredited by the French competitiveness cluster Alsace BioValley

Co-accredited by the French competitiveness cluster Lyonbiopôle

Strategic business area: Human Medicines

Application fields: Oncology

Technological approaches / Keywords: Chemotherapy, Immunotherapy

Stage of development at the beginning of the project: Discovery, Preclinical development


Led by a consortium headed by ElsaLys Biotech, this project seeks to validate and industrially produce an anti-TYRO3 antibody candidate for the treatment of leiomyosarcoma and metastatic bladder cancer. This should lead to two products: a candidate drug with an original mechanism of action in oncology and a new production system reducing monoclonal antibody production costs. Original in terms of its form and substance, this project provides a response to a twofold public health challenge: speeding up the development of new therapeutic antibodies against cancers and reducing their price, which notably entails decreasing their production cost.


The TYROMAB project aims at developping the French biomanufacturing industry and reduce the burden of cancer through the development of a novel therapeutic antibody.

Innovative assets

Innovative assets

During the TYROMAB project, a new and highly distinctive line of products, based on a new cellular tool will be produced. The TYROMAB project’s objective is also to develop an original therapeutic antibody: anti-TYRO3, that in its final format, could combine 2 mechanisms of action : Inhibit tumor cell growth and stimulate the anti-tumor immune response.    

En poursuivant votre navigation sur notre site, vous acceptez l'utilisation des cookies et la collecte de vos données et informations personnelles par Lyonbiopôle, dans les finalités de mesurer le trafic sur le site Web, de fournir des statistiques et de vous proposer des contenus adaptés à vos centres d’intérets. Pour exercer vos droits d'accès, de rectification, d'opposition, de suppression et de portabilité, conformément au règlement général sur la protection des données (UE n°2016/679), vous etes informés que vous pouvez envoyer votre demande à dpo@lyonbiopole.com. Plus de détails sont disponibles en cliquant ici J'accepte